This Article Full Text Full Text (PDF) All Versions of this Article: 37/11/2751    most recent 01.STR.0000246611.21999.5dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Earnshaw, S. R. Articles by Rosand, J. Search for Related Content PubMed PubMed Citation Articles by Earnshaw, S. R. Articles by Rosand, J. Related Collections Other Stroke Treatment - Medical Acute Cerebral Hemorrhage

(Stroke. 2006;37:2751.)
© 2006 American Heart Association, Inc.

Original Contributions

Cost-Effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage

From RTI Health Solutions (S.R.E., M.R.W.), Research Triangle Park, NC, USA; Novo Nordisk Inc (A.V.J.), Princeton, NJ, USA; and Vascular and Critical Care Neurology and Center for Human Genetic Research (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Correspondence to Stephanie R. Earnshaw, 200 Park Offices Drive, PO Box 12194, Research Triangle Park, NC 27709. E-mail searnshaw{at}rti.org

Background and Purpose— Intracerebral hemorrhage (ICH) is among the most costly and debilitating forms of stroke. Results from a recent Phase IIb clinical trial demonstrate that administration of recombinant activated factor VII (rFVIIa) reduces ICH mortality and improves functional outcome. In the current analysis, we examine the cost-effectiveness of early treatment with rFVIIa for ICH in the United States.

Methods— A decision-analytic model was developed to estimate the lifetime costs and outcomes associated with rFVIIa treatment at doses of 40, 80 and 160 µg/kg compared with current standard of care in treating ICH, from a US third-party payer perspective. The patient population was similar to that of the Phase IIb clinical trial. Model structure and inputs were obtained from published literature, clinical trial data, claims databases, and expert opinion. All costs are presented in 2005 US dollars. Outcomes included incremental cost per life-year (LY) saved and incremental cost per quality-adjusted life-year (QALY) gained. Costs and outcomes were discounted at 3% annually. Univariate and multivariate sensitivity analyses were conducted to assess model robustness.

Results— Compared with standard care, treatment with rFVIIa 40 µg/kg, and 160 µg/kg results in total lifetime cost-effectiveness ratios of $6308/QALY and $3152/QALY, respectively. Treatment with rFVIIa 80 µg/kg was found to be cost saving and a gain of 1.67 QALYs is achieved over a patient’s lifetime. These results are robust to changes in input parameters.

Conclusions— Treatment of ICH with rFVIIa 40 µg/kg and 160 µg/kg appears to be cost-effective ($50 000/QALY). At the 80 µg/kg dose, rFVIIa was not only cost-effective, but also cost saving.

Key Words: cost-effectiveness analysis • economics • intracerebral hemorrhage • stroke management

This article has been cited by other articles:

				W. Lo, K. Zamel, K. Ponnappa, A. Allen, D. Chisolm, M. Tang, B. Kerlin, and K. O. Yeates The Cost of Pediatric Stroke Care and Rehabilitation Stroke, January 1, 2008; 39(1): 161 - 165. [Abstract] [Full Text] [PDF]

				F. Perez-Alvarez, C. Serra, J. Macia, and L. Mayol rFVII for Pediatric Acute Intracranial Hemorrhage Stroke, July 1, 2007; 38(7): e63 - e64. [Full Text] [PDF]

				rFVIIa Is Cost-Effective for Acute ICH Journal Watch Neurology, February 6, 2007; 2007(206): 2 - 2. [Full Text]